Akero Therapeutics Inc (AKRO)
21.08
+1.12 (+5.61%)
USD |
NASDAQ |
Jan 20, 13:02
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 735.45M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -32.54% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.703 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
01/04 16:05
Yahoo
11/26 17:28
Yahoo
11/17 10:07
MT Newswires
11/15 10:11
MT Newswires
11/15 10:10
MT Newswires
11/15 09:23
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/16/2022* | -- | Results | Q4 2021 | -- | -0.83 | -- | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.70 | -0.91 | 22.80% | |
| 08/13/2021 | -- | Results | Q2 2021 | -0.83 | -0.71 | -17.62% | |
| 05/13/2021 | -- | Results | Q1 2021 | -0.43 | -0.94 | 54.06% | |
| 03/16/2021 | -- | Results | Q4 2020 | -0.86 | -0.60 | -44.41% | |
| 11/12/2020 | -- | Results | Q3 2020 | -0.63 | -0.67 | 6.11% | |
| 08/12/2020 | -- | Results | Q2 2020 | -0.57 | -0.62 | 7.73% | |
| 05/13/2020 | -- | Results | Q1 2020 | -0.42 | -0.61 | 31.15% |
*Estimated Date/Time
Earnings
Profile
Edit
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
| URL | https://www.akerotx.com |
| Investor Relations URL | https://ir.akerotx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 16, 2022 |
| Last Earnings Release | Nov. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Edit comparables
Annual Total Returns Versus Peers
Edit comparables
As of January 19, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 98.23M |
| Net Income (TTM) | -98.06M |
| Total Assets (Quarterly) | 223.53M |
| Total Liabilities (Quarterly) | 24.90M |
| Shareholders Equity (Quarterly) | 198.63M |
| Cash from Operations (TTM) | -76.38M |
| Cash from Investing (TTM) | 48.18M |
| Cash from Financing (TTM) | 0.418M |
Ratings
Profile
Edit
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
| URL | https://www.akerotx.com |
| Investor Relations URL | https://ir.akerotx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 16, 2022 |
| Last Earnings Release | Nov. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| BBC | 166395.0 USD | 0.67% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| Stocktwits | AKRO Tweets |